Cargando…

Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?

In chronic lymphocytic leukemia (CLL), there is a growing interest for minimal residual disease (MRD) monitoring, due to the availability of drug combinations capable of unprecedented complete clinical responses. The standardized and most commonly applied methods to assess MRD in CLL are based on fl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Del Giudice, Ilaria, Raponi, Sara, Della Starza, Irene, De Propris, Maria Stefania, Cavalli, Marzia, De Novi, Lucia Anna, Cappelli, Luca Vincenzo, Ilari, Caterina, Cafforio, Luciana, Guarini, Anna, Foà, Robin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727319/ https://www.ncbi.nlm.nih.gov/pubmed/31555576 http://dx.doi.org/10.3389/fonc.2019.00689

Ejemplares similares

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
por: Della Starza, Irene, et al.
Publicado: (2019)

Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia
por: Cafforio, Luciana, et al.
Publicado: (2021)

Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia
por: Della Starza, Irene, et al.
Publicado: (2023)

Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
por: Assanto, Giovanni Manfredi, et al.
Publicado: (2023)

Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia‐positive acute lymphoblastic leukaemia
por: Ansuinelli, Michela, et al.
Publicado: (2021)

Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia
por: Marinelli, Marilisa, et al.
Publicado: (2016)

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913
por: Chiaretti, Sabina, et al.
Publicado: (2020)

High rate of minimal residual disease responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)
por: Mauro, Francesca R., et al.
Publicado: (2020)

P1232: NON-INVASIVE MINIMAL RESIDUAL DISEASE ANALYSIS BY IMMUNOGLOBULIN GENE REARRANGEMENTS ON CIRCULATING TUMOR DNA PREDICTS THE OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
por: Soscia, Roberta, et al.
Publicado: (2023)

Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab
por: Peragine, Nadia, et al.
Publicado: (2020)

Sialylation regulates migration in chronic lymphocytic leukemia
por: Natoni, Alessandro, et al.
Publicado: (2023)

Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network
por: Mantoan, Barbara, et al.
Publicado: (2021)

TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia
por: Puzzolo, Maria Cristina, et al.
Publicado: (2021)

Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia
por: Della Starza, Irene, et al.
Publicado: (2021)

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study
por: Mauro, Francesca R., et al.
Publicado: (2023)

Gamma Heavy Chain Disease Associated with T-Cell Large Granular Lymphocyte Lymphoproliferative Disorder: Case Report and Literature Review
por: Bisegna, Maria Laura, et al.
Publicado: (2023)

Utility of Flow Cytometry Ascitic Fluid Analysis for Rapid Diagnosis of B-Cell Peritoneal Lymphomatosis
por: Bisegna, Maria Laura, et al.
Publicado: (2022)

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study
por: Mauro, Francesca Romana, et al.
Publicado: (2021)

Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: An Italian Monocentric Experience
por: Fazio, Francesca, et al.
Publicado: (2023)

Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients
por: Chan, Thomas Sau-Yan, et al.
Publicado: (2017)

Sialofucosylation Enables Platelet Binding to Myeloma Cells via P-Selectin and Suppresses NK Cell-Mediated Cytotoxicity
por: Natoni, Alessandro, et al.
Publicado: (2023)

PB1711: DROPLET DIGITAL PCR DETECTION OF THE T315I BCR::ABL1 KD MUTATION IN ADULT PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
por: Cardinali, Deborah, et al.
Publicado: (2023)

P861: SIALOFUCOSYLATED STRUCTURES ENABLE PLATELET BINDING TO MYELOMA CELLS CONFERRING PROTECTION FROM NK-MEDIATED CYTOTOXICITY
por: Natoni, A., et al.
Publicado: (2022)

Long-Term Host Immune Modulation Following Tisagenlecleucel Administration in Patients with Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic Leukemia
por: Guarini, Anna, et al.
Publicado: (2023)

P04 MULTIPARAMETRIC FLOW CYTOMETRY REFINES RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
por: Fazio, F., et al.
Publicado: (2023)

Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial
por: Bassan, Renato, et al.
Publicado: (2023)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Drug resistance and minimal residual disease in multiple myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives
por: Mina, Roberto, et al.
Publicado: (2020)

Ara-C, Idarubicine and Gentuzumab Ozogamicin (AIM) as Salvage Treatment in Advanced Acute Myeloid Leukemia Patients
por: Capria, Saveria, et al.
Publicado: (2012)

Limits On Cosmology From Infrared Galaxy Number Counts
por: De Propris, R
Publicado: (2000)

Hybrid minimally invasive esophagectomy: a goal or a step?
por: Piessen, Guillaume, et al.
Publicado: (2020)

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020)

Minimal residual disease in pediatric ALL
por: Pui, Ching-Hon, et al.
Publicado: (2017)

Minimal Residual Disease, Metastasis and Immunity
por: Badia-Ramentol, Jordi, et al.
Publicado: (2021)

Methods to detect minimal residual disease
por: Haferlach, Torsten
Publicado: (2018)

IL2 treatment for cancer: from biology to gene therapy.
por: Foa, R., et al.
Publicado: (1992)

Eradication of Measurable Residual Disease in AML: A Challenging Clinical Goal
por: Bernasconi, Paolo, et al.
Publicado: (2021)

Selective splenic artery embolization for the treatment of thrombocytopenia and hypersplenism in paroxysmal nocturnal hemoglobinuria
por: Araten, David J, et al.
Publicado: (2014)

Minimal Cues of Possession Transfer Compel Infants to Ascribe the Goal of Giving
por: Tatone, Denis, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9kvnh1qc32r5na3ffimb3j2a2f